AP surges on strong orders, AZN plunges after trial miss, LEVI slips on tariff outlook, MDA drops on dilution—read more.
Zacks.com on MSN
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
In the latest close session, Astrazeneca (AZN) was down 3.85% at $171.61. This move lagged the S&P 500's daily gain of 0.42%.
Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...
In the most recent trading session, Astrazeneca (AZN) closed at $185.68, indicating a +1.45% shift from the previous trading ...
Zacks Investment Research on MSN
Why AstraZeneca (AZN) dipped more than broader market today
Astrazeneca (AZN) ended the recent trading session at $183.86, demonstrating a -3.04% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of ...
AstraZeneca shares tumbled nearly 10% in London after a late-stage trial for an experimental heart disease failed to meet its ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
AstraZeneca (LSE:AZN) shares have been in focus after fresh collaboration news, with investors weighing how new research ...
Zacks Investment Research on MSN
AZN vs. ILMN: Which stock should value investors buy now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN) and Illumina (ILMN). But which of these two stocks offers value ...
In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca, with a price target of £189.00. Unlock powerful investing tools and data-driven insights with TipRanks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results